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Abstract
Background: Endometriosis is a common cause of chronic pelvic pain which can relapse after surgery, yet little
research has been conducted on women’s experience of medical treatments for prevention of recurrence and the
influence of this on participation in clinical trials.
Methods: This study explored women’s past experiences with medical treatments for endometriosis symptoms and
the impact this has on their motivation to enter the pilot phase of a post-conservative surgery clinical trial, PRE-EMPT:
Preventing Recurrence of Endometriosis by Means of long acting Progestogen Therapy. Qualitative methodology was
adopted, involving semi-structured interviews in three UK cities, and one focus group was used to collect data from
women with a diagnosis of endometriosis participating in the PRE-EMPT trial.
Results: Ten women were interviewed individually and four took part in the focus group discussion. Women’s
willingness to enter the PRE-EMPT trial was bound up with their previous experiences, present situation and future
expectations of medication, as well as the control offered by flexible randomisation which allows the option to reject
a particular treatment post-surgery.
Conclusion: Women were strongly influenced by previous experience and personal circumstances in their decision
to enter the PRE-EMPT trial. This decision was facilitated by the ability to ‘opt out’ of the treatment arm(s) they found
unacceptable. This element of choice offered patients a sense of control in the randomisation process and has important
implications for clinical trial design and recruitment.
Trial registration: ISRCTN97865475. EUDRACT number 2013–001984-21.
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Background
Endometriosis is a chronic condition in women where
endometrial tissue found outside the uterus produces an
inflammatory response [1]. It has often been called the en-
igmatic disease; its aetiology is not clearly understood [2,
3], symptoms are extremely variable and there is only
weak evidence underpinning many common medical
treatments [4–6]. While some women with laparoscopic
evidence of pelvic endometriosis experience extreme pain,
fatigue and infertility, others remain asymptomatic [5] and
the severity of symptoms is not correlated with the extent
of disease [7]. Many qualitative studies have been under-
taken that seek to gain insight into the experience of
endometriosis, but a search using the relevant databases
for qualitative studies on health and health care revealed
no study where the primary purpose was to explore
women’s experiences of medical treatments for endomet-
riosis. However, this is an important issue for many symp-
tomatic participants in endometriosis research. Women
describe in graphic detail the extent of their pain and the
impact it has on their lives, often living with the condition
for many years before receiving a diagnosis [8–12]. They
report going through cycles of ineffective medical
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treatments [9, 12–14], often with unpleasant side effects
[7, 10, 15, 16]. Many of these treatments are also
contra-indicated in women who wish to become pregnant.
The lack of effective treatments will sometimes lead
women to abandon medical treatment altogether [8] or to
seek self-management strategies through alternative and
complementary therapy [17].
Laparoscopic excision of endometriotic lesions is consid-
ered to be effective in pain outcomes, in comparison to
diagnostic surgery alone [18], but the evidence is weak and
risks of relapse and reoccurrence of symptoms are high
[19]. Prevention of recurrence of pain symptoms following
surgery involves the use of agents which reduce circulating
levels of oestrogen, causing shrinkage of remaining endo-
metriotic deposits and prevention of de novo lesions. A
number of drugs, including long-acting reversible contra-
ceptives (LARCs) are in current use, but there is no
consensus as to which is most effective and cost effective
(see latest trial protocol: https://njl-admin.nihr.ac.uk/docu-
ment/download/2011878). There is a need, therefore, to
assess the clinical effectiveness of the available
post-surgical treatment options in terms of controlling the
recurrence of endometriosis and improving quality of life.
The PRE-EMPT trial (see Table 1) aims to evaluate the
clinical effectiveness, cost effectiveness and acceptability of
such treatment in women following conservative surgery
for endometriosis pain. The pilot phase of this trial [20]
allowed flexible randomisation (i.e. the ability of partici-
pants to opt out of one or two treatments, as long as one
LARC and one non-LARC was accepted) between four
post-surgical options in preventing the recurrence of
endometriosis:
1) Combined oral contraceptive pill (COCP), containing
30 μg ethinylestradiol and 150 μg levonorgestrel
taken either continuously or cyclically;
2) Levonorgestrel intrauterine system (LNG-IUS), as a
20-μg per day formulation;
3) Depot medroxyprogesterone acetate (DMPA), as a
150-mg injection every 12 weeks;
4) No medical treatment initiated post-laparoscopy.
As part of the pilot study for the PRE-EMPT trial, a
stand-alone qualitative study was undertaken. Participa-
tion in clinical trials, in particular randomised controlled
trials (RCTs), has always been problematic, with many
failing to recruit anticipated numbers [21]. Both quanti-
tative and qualitative studies have considered why this is
the case, but their findings have had little effect on over-
all recruitment [22]. This article will present the findings
from the qualitative study within the PRE-EMPT clinical
trial which had the aim of exploring women’s previous
Table 1 The PRE-EMPT trial protocol summary
Design A randomised, pragmatic multicentre trial with integrated economic evaluation
Setting Up to 40 NHS hospitals within the UK
Target population Women of reproductive age, who are undergoing laparoscopy to investigate whether their pelvic pain is due to endometriosis
Exclusion criteria Current infertility, immediate plans to conceive
Health technologies
assessed
The main comparison is long-acting reversible contraception (LARC) versus combined oral contraceptive pill (COCP). Participants
can have a pre-randomisation choice of LARC (or alternatively one will be randomly allocated):
i) Levonorgestrel-releasing intra-uterine system (LNG-IUS) (fitted by a gynaecologist) or
ii) 3 monthly depot medroxyprogesterone acetate (DMPA) injections (administered by the patient’s gynaecologist or general
practitioner); subcomparisons will be stratified by this choice
Outcomes The primary outcome is the recurrence of symptoms as evaluated by the pain domain of the Endometriosis Health Profile–30
(EHP-30) questionnaire at 36 months post-randomisation. The EHP-30 is a validated, responsive health-related quality of life
measure for endometriosis. It will also be assessed prior to randomisation and at 6, 12 and 24 months.
Secondary outcomes:
• All other symptom and quality of life (QoL) domains of the EHP-30
• Non-menstrual pelvic pain and dysmenorrhea measured by 0–100 visual analogue (VAS) pain scale
• Fatigue, as measured by the Fatigue Severity Score
• Menstrual regularity
• Generic QoL (EQ-5D) and capabilities, as measure of wellbeing (ICE-CAP)
• Further diagnostic and therapeutic surgery for endometriosis (as a proxy for recurrence)
• Discontinuation rates of randomised treatment, with reasons for change, serious adverse events
• Cost per quality-adjusted life year (QALY) and cost per change in symptom score.
• An increased knowledge of issues identified as important by the participants regarding their treatment and its impact on their lives
Analysis The main comparison will be LARC vs COCP, with sub-comparisons of the groups where the intention is to treat with either
LNG-IUS or DMPA if randomised to LARC. The primary outcome will be analysed using a linear regression model including a
variable for each treatment group and including baseline score and the minimisation factors as covariates. Effect sizes will be
presented as point estimates and 95% confidence intervals. Standard statistical methods will be used for other outcomes.
All analysis will be by intention to treat.
Sample The study will have 90% power (p = 0.05) to detect an 8-point difference in the main comparison assuming the standard deviation
of the EHP-30 pain domain is 22 points. This will require 160 women per group, 320 in total. To account for 20% loss to follow-up,
this target has been inflated to 400 women in total
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experience of medical treatments for endometriosis
symptoms and the impact this has on their motivation
to enter a clinical trial post conservative surgery.
Methods
Design
A qualitative approach to the study was considered ap-
propriate as the aim of the study was to gain insight into
women’s experiences and motivations and also to ex-
plore issues of importance to them rather than to adhere
strictly to a script. Narratives are an important way for
people to explain disruptive events in their lives, and the
use of narrative interviews and a focus group in this
study allowed women to reflect on living with endomet-
riosis and to raise the issues that had greatest impact on
their lives [23]. Three sites taking part in the PRE-EMPT
trial, Aberdeen Royal Infirmary, Birmingham Women’s
Hospital and Edinburgh Royal Infirmary, all in the UK,
took part in the qualitative study, which comprised a
focus group discussion and individual interviews (see
Table 2). The focus group and semi-structured interview
topic guides were informed by available literature on
women’s experiences of medical treatments for endo-
metriosis symptoms, as well as the expertise of the
PRE-EMPT Trial Management Group. As a means of es-
tablishing rapport, at the beginning of interviews and
the focus group, some demographic data were collected.
Favourable ethical approval for this study was obtained
from the North of Scotland Research Ethics Committee
and site-specific permission from the NHS Trusts of
each of the hospitals involved.
Recruitment
Purposive sampling, that is sampling people who are
relevant to the research question [24], was undertaken.
All of the women recruited had been randomised in the
PRE-EMPT trial and had given additional consent for
the stand-alone qualitative study following discussion
with the local research nurses. They were then
approached by the researchers (AW and SB) and asked
to take part in either the focus group (if from Aberdeen)
or an individual interview. Formal written consent was
obtained by the research nurses prior to interviews and
the focus group; researchers reiterated consent verbally
on the day of interview/focus group. The focus group
and interviews were carried out by AW and SB, both ex-
perienced qualitative researchers with an interest in
women’s reproductive health. To foster open and honest
discussions, the researchers explicitly stated that they
were university academics separate from hospitals in-
volved in the trial and reinforced the confidential and
anonymous nature of women’s participation. In appreci-
ation of their time, participants were given a £20 gift
voucher at the end of their interview or the focus group.
Data collection
The focus group discussion took place at Aberdeen
Royal infirmary. Initially, six women agreed to take part,
but only four attended. The focus group discussion
elicited women’s past experiences with the treatments
included in the trial and examined their willingness to
accept each treatment post-surgery and whether their
inclusion in any of them would constitute a barrier to
continuation within the study. Three women were inter-
viewed in person (from Birmingham) and seven were
interviewed over the telephone (from Edinburgh and
Aberdeen) (n = 10). Telephone interviews offered a flex-
ible means to include women from a wide geographical
spread. Individual interviews allowed respondents to feel
more relaxed and able to address issues concerning their
endometriosis treatment experiences that may have been
too sensitive to discuss in a focus group setting [25].
The focus group and interviews were digitally audio re-
corded with consent and fully transcribed verbatim.
Written consent was obtained to use anonymised
Table 2 Focus group and interview schedules
1. Past medical treatment experiences
• Tell me about the types of medical treatments you have tried
• Prompts: Why did you try [names of treatments]? Who influenced
your decision? What were your expectations?
• Tell me about your experiences of …. [names of treatments]
• Prompts: Effectiveness/ineffectiveness of treatment? How long
effective for? Side effects?
2. Views on medical treatments offered in PRE-EMPT
After undergoing surgery, there are four possible treatments—how do
you feel about:
• ‘The pill’
• ‘The coil’
• ‘Depo Provera’
• No treatment
• [For each treatment above] Prompt: (Un)Acceptable? Why? Past
experiences? Future hopes? Do you think the treatment would be
more effective post-surgery?
• Were there any treatments that you would not accept? Which? Why?
3. Views on medical trials [General]
• What do you think about medical trials?
• What do you think about randomisation?
• Prompts: Understandings of randomisation/how treatment is
allocated. Randomisation acceptable to you? Is the possibility of not
getting treatment acceptable?
4. Views on participation in PRE-EMPT trial
• What do you think about the PRE-EMPT trial?
• Prompts: Hopes for the trial? Concerns about the trial?
• Why did you take part in the PRE-EMPT trial?
• Prompts: What did you hope to gain from participating? What were
your concerns about participating?
• What would be a barrier to you participating?
• Prompts: Personal factors? Time/travel costs? Trial factor? Concerns
about treatment availability/randomisation?
• Did you have a preference for which arm you would be randomised
to? Why? Why not?
• Is this a worthy trial? Why? Why not?
• How do you feel about the length of the trial (3 years)?
5. Concluding questions
• Is there anything we did not discuss that you would like to talk about?
• Do you have any questions for me?
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extracts from the transcripts in publications. The focus
group lasted 1 h and the interviews were 25 to 60 min
in duration. All data were collected in January and
February 2015.
Analysis
Thematic analysis [24] was carried out by the qualitative
research team, which consisted of two qualitative leads
(ED and GJ) and two research assistants (AW and SB).
AW and SB independently read the transcripts line by
line, identifying emergent themes and created initial
codes. AW and SB brought these codes together to cre-
ate a coding framework, and AW coded the transcripts
with NVIVO 10. AW employed constant comparison, an
iterative method of analysis, searching for each themed
code throughout the entire data set (focus group, inter-
view and telephone interview data), comparing all in-
stances until no new themes were identified. Saturation
was deemed to have been reached when no new themes
were emerging from additional interview data. ED and
GJ each independently read proportions of the transcrip-
tions. The team jointly discussed and agreed upon com-
mon patterns and broader themes from women’s
experiences and perspectives on treatment acceptability.
Dissident views and areas of diversity among the team
were also considered and resolved. To establish the
trustworthiness [26] of the analysis, the four researchers
independently read the transcripts and compared find-
ings from the two parts of the data collection process.
Although generalisation is not an aim of qualitative re-
search, we were able to show consistency with the exist-
ing literature on women’s experience of symptomatic
endometriosis.
Results
In reporting this study, standards for reporting qualita-
tive research (SRQR) were adopted [27] (see Table 3).
Women participating in both the focus group and indi-
vidual interviews shared their views and experiences of
medical treatments and their motivation for enrolling in
the PRE-EMPT trial. As no novel treatment was on
offer, many women had previous experience of treat-
ments available as part of the RCT (either as endometri-
osis treatment or for contraceptive purposes), which
strongly influenced their acceptability.
Sample
The ages of the 14 participating women varied from 19 to
36 years, and experience of symptoms of endometriosis
varied from 2.5 to 16 years. There was a range of sympto-
mology, treatment histories and allocated treatment
groups within the trial. A table detailing overall baseline
characteristics of the sample is provided in Table 4.
Personal circumstances and past experiences
Most women in both the FG and interviews spoke of
past experiences of one or more of the interventions of-
fered by the trial. Although some women had only re-
cently received a diagnosis, nearly all had a long history
of symptoms and had received at least one treatment.
Women described how endometriosis was affecting all
aspects of their lives, particularly work and personal
relationships.
And then it was just getting unbearable, like difficult
to walk. And then sex with my now ex-boyfriend was
awful, which probably contributed to the end of the
relationship. (P7, interview).
But I think it was just more I was getting to the point
that I had to cancel nights out, days out, holidays and
everything because the pain was just [unbearable]
(P1, Focus Group).
Women graphically described the pain they experi-
enced and the strategies that they would adopt to man-
age everyday life.
Because you have the pain all the time, but then there’s
that other pain, and you brace yourself - is the only way
I can describe it. But I would literally start running
through my work diary thinking, ‘Can I manage this
day? Is there anything I can move around? Can I make
it to the end of the week?’ I would have real panic
thinking, ‘I’m not going to make it through today, I’m
going to have to cancel clinics.’ I think that’s the bit that
took over my life. (P4, Focus Group).
A number of women spoke of being dismissed and not
taken seriously in the past and of being misdiagnosed,
which added to delays in receiving treatment. For them,
the trial was a sign that ‘someone was taking an interest’
in endometriosis, which encouraged them to participate.
Women had complex views in regard to whether
treatments they had used prior to surgery would be
more effective post-surgery. For example, some women
(n = 3) had negative past experiences with both the
COCP and DMPA. While they would not accept the
latter post-surgery because of unpleasant side effects,
they were willing to accept the COCP as they believed
it may be more effective post-surgery. ‘I know [the pill]
didn’t help in the past, but, you know it might change
now. Since I’ve had an operation, it might help’ (P5,
interview). Other women (n = 3) did not believe a par-
ticular hormonal treatment would have more efficacy
post-surgery as they had undergone surgeries before
and found the treatment(s) equally ineffective or nega-
tive after. ‘I didn’t really think I would have a different
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Table 3 Standards for reporting qualitative research (SRQR) https://www.ncbi.nlm.nih.gov/pubmed/24979285
Page/line
no(s).
Title and abstract
Title - Concise description of the nature and topic of the study Identifying the study as qualitative or indicating the approach
(e.g., ethnography, grounded theory) or data collection methods (e.g., interview, focus group) is recommended
P1
Abstract - Summary of key elements of the study using the abstract format of the intended publication; typically includes background,
purpose, methods, results, and conclusions
P1
Introduction
Problem formulation - Description and significance of the problem/phenomenon studied; review of relevant theory and empirical
work; problem statement
P1/30-P3/3
Purpose or research question - Purpose of the study and specific objectives or questions P2/31-P3/3
Methods
Qualitative approach and research paradigm - Qualitative approach (e.g., ethnography, grounded theory, case study, phenomenology,
narrative research) and guiding theory if appropriate; identifying the research paradigm (e.g., postpositivist, constructivist/ interpretivist)
is also recommended; rationale**
P3/6-P3/30
P8/12-16
Researcher characteristics and reflexivity - Researchers’ characteristics that may influence the research, including personal attributes,
qualifications/experience, relationship with participants, assumptions, and/or presuppositions; potential or actual interaction between
researchers’ characteristics and the research questions, approach, methods, results, and/or transferability
P3/46-50
Context - Setting/site and salient contextual factors; rationale** P3/55-70
Sampling strategy - How and why research participants, documents, or events were selected; criteria for deciding when no further
sampling was necessary (e.g., sampling saturation); rationale**
P3/34-54
Ethical issues pertaining to human subjects - Documentation of approval by an appropriate ethics review board and participant
consent, or explanation for lack thereof; other confidentiality and data security issues
P3/26-29
P10/34-38
Data collection methods - Types of data collected; details of data collection procedures including (as appropriate) start and stop
dates of data collection and analysis, iterative process, triangulation of sources/methods, and modification of procedures in response
to evolving study findings; rationale**
P3/52-P4/4
Data collection instruments and technologies - Description of instruments (e.g., interview guides, questionnaires) and devices
(e.g., audio recorders) used for data collection; if/how the instrument(s) changed over the course of the study
P3/69-P4/4
P 3 Table 2
Units of study - Number and relevant characteristics of participants, documents, or events included in the study; level of participation
(could be reported in results)
P4/44-49
P3 Table 4
Data processing - Methods for processing data prior to and during analysis, including transcription, data entry, data management
and security, verification of data integrity, data coding, and anonymization/de-identification of excerpts
P3/69-P4/4
Data analysis - Process by which inferences, themes, etc., were identified and developed, including the researchers involved in data
analysis; usually references a specific paradigm or approach; rationale**
P4/6-32
Techniques to enhance trustworthiness - Techniques to enhance trustworthiness and credibility of data analysis (e.g., member checking,
audit trail, triangulation); rationale**
P4/24-31
Results/findings
Synthesis and interpretation - Main findings (e.g., interpretations, inferences, and themes); might include development of a theory
or model, or integration with prior research or theory
P4/50-58
P4/80-P6/4
P6/12-P7/48
P7/57-P8/10
Links to empirical data - Evidence (e.g., quotes, field notes, text excerpts, photographs) to substantiate analytic findings P4/60-P7/88
Discussion
Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation
of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope
of application/generalizability; identification of unique contribution(s) to scholarship in a discipline or field
P8/11-P9/73
P9/100-P10/
15
Limitations - Trustworthiness and limitations of findings P9/117-30
Other
Conflicts of interest - Potential sources of influence or perceived influence on study conduct and conclusions; how these were
managed
P10/58-60
Funding - Sources of funding and other support; role of funders in data collection, interpretation, and reporting P10/20-23
**The rationale should briefly discuss the justification for choosing that theory, approach, method or technique rather than other options available, the
assumptions and limitations implicit in those choices, and how those choices influence study conclusions and transferability. As appropriate the rationale for
several items might be discussed together
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experience [with hormonal treatments] because I’ve
had the surgery before’ (P7, interview).
Current life circumstances, particularly in relation to
reproduction, also influenced decision making regarding
acceptability of treatment options.
I do not want a child right now, so it’s quite good that
I am on the pill and that’s monitoring the endometriosis
and that side of things as well. … So I think that’ll vary
for everyone. I mean, I think, you know, depending on
what age you are and what age you want to have
children or where you are going in life, career-wise and
things as well, I think that will vary. (P8, interview).
Views on individual treatment options
The majority of participants reported previous experi-
ence with one or more of the medications on offer in
the trial. No one option, which included the combined
COCP, LNG-IUS, DMPA, and no treatment, was found
to be more or less acceptable by participants. This was
similar to results of the clinical trial pilot study, which
found that no particular treatment combinations were
chosen more than others [20].
When women found the COCP an unacceptable treat-
ment option, this was due to experience of negative side
effects in the past (including weight gain, mood swings
and erratic periods) or because it had been ineffective in
the management of their symptoms. As one woman
states, ‘[The pill] didn’t help at all. I was getting my pe-
riods, like, quite a lot more than I should have. And it
didn’t help with the pain’ (P4, interview). Those who
found the pill acceptable did so because of success with
it as a treatment option in the past, the ease with which
they could both start and discontinue the pill, and a
need for contraception.
Some women expressed ambivalence about the accept-
ability of COCP. For example, one participant found that
it was not completely effective at controlling her endo-
metriosis symptoms in the past, but she was willing to
accept it as a treatment option post-surgery as she
regarded it as the best of the choices available. Further-
more, on the COCP, she states that ‘the pain still comes
and goes, but the bleeding is a lot more under control. I
feel like now I control [my endometriosis] when I start
and stop the pill as opposed to [endometriosis] control-
ling my life’. (P8, interview). Other women who had lim-
ited success with the COCP in the past were willing to
accept it as a treatment option because they would be
prescribed a different contraceptive pill to the one(s)
previously taken or they believed that post surgery, the
pill may be more effective.
Women did not accept LNG-IUS as a treatment op-
tion if they had previous negative side effect experiences
(including discomfort, cramping, weight gain, increased
bleeding, poor fittings and infections) or because of
negative experiences of friends and family members,
who had usually used it for contraceptive purposes. For
example, one woman rejected LNG-IUS as her mother
had become pregnant while using it. Those who found
LNG-IUS acceptable did so because they had no previ-
ous experience with it and/or appreciated its conveni-
ence as a long-acting treatment, as once the coil was
inserted, ‘you could forget about it’ (P5, interview).
Table 4 Baseline characteristics of sample
(n = 14)
Age, years Mean (SD) 27.9
(5.7)
Ethnic group, n (%) White British 12 (86)
Black/Black British
Caribbean
1 (7)
Asian/Asian British
Pakistani
1 (7)
Missing –
Parity, n (%) 0 12 (86)
1 1 (7)
2 1 (7)
Missing –
Employment status, n (%) Full-time 10 (72)
Part-time 1 (7)
Unemployed 1 (7)
Student 2 (14)
Missing –
Previous treatment experiences
with LNG-IUS, DMPA or COCP, n (%)
All 2 (14)
LNG-IUS and COCP 1 (7)
DMPA and COCP 5 (36)
COCP 6 (43)
Missing –
Stage of endometriosis, n (%) I 5 (35)
II 4 (29)
III 4 (29)
IV 1 (7)
Missing –
Number of previous laparoscopies,
n (%)
0 7 (50)
1 5 (36)
2 2 (14)
Missing –
Extent of excision as judged by
surgeon, n (%)
Complete 11 (79)
Missing –
EHP-30 pain score at baseline Mean (SD) 59.7
(9.7)
Missing –
Denny et al. Pilot and Feasibility Studies           (2018) 4:168 Page 6 of 10
Participants who would not accept DMPA as a treat-
ment option had found it ineffective in the management
of their symptoms and/or had highly negative experi-
ences (including heavier/more frequent periods and mi-
graines) in the past. Two women found the repeat visits
required to receive the injections inconvenient, as one
states ‘I work, I go to college, I’m trying to have as much
of a life as I can when I’m not in pain...The thought of
going to the doctor, it’s quite far away from me as well…
I just don’t think it would be for me’ (P5, interview).
Those who accepted the DMPA as a treatment option
did so because it was a new option they had no previous
experience with and were therefore open to trying it.
Women who found randomisation to non-treatment
unacceptable did so as they were concerned their
endometriosis symptoms would return more quickly
post-surgery or because they required hormonal contra-
ception. One woman enrolled in this arm of the trial
expressed concern that although happy with this option
now, her life circumstances may change and she could
require a hormonal treatment for contraceptive purposes
on becoming sexually active. Those who found
non-treatment acceptable reported feeling they were
willing to let their body ‘have a break’ (P6, interview)
from hormonal treatments and to ‘let [their] body settle’
(P5, interview) after surgery and to assess the efficacy of
the surgery in relation to their symptoms.
Decision making regarding treatments and views on
randomisation
Women found randomisation acceptable as they had an
element of choice over which treatment groups to be
randomised to (see Table 1).
I obviously have tried pretty much every treatment for
endometriosis before surgery. So that would obviously
have a big bearing on me. If something’s not worked
before, you know, you would as much as [pauses], like
say, if a doctor told me to take something just to try
it, of course I would want to. But I think sometimes
you know your body better … especially if you’ve had
[the treatments] in the past. (P8, interview)
Many women viewed randomisation as part of a ‘trial
and error’ process that is necessary to learn which
treatment options work best for individual women as
‘every [treatment] works differently with everyone’s
body’ (P4, interview). Half of the participants (n = 7) re-
ported that without the option to opt out of a particular
treatment group (or groups), they would have declined
trial participation. Two women viewed randomisation
positively as it relieved them from the burden of choos-
ing a treatment without adequate knowledge of the op-
tions. Randomisation was seen as ‘quite a good thing’, by
one such participant as it ended the stress of deciding
between multiple options and the confusion of ‘other
people telling you what to have, putting you off things,
it’s better just the doctor saying, “That’s what you’re hav-
ing.” Try it and that’s it’ (P5, interview).
Expectations of trial participation
Women chose to participate in the trial for reasons of
altruism and self-interest. Participants expressed a desire
to help others with endometriosis and to prevent them
‘suffering’ from the same physical, emotional and health
consequences they had experienced. Many hoped the
trial would ‘raise awareness’ and shorten pathways to
diagnosis, even though these were not aims of the trial.
‘It took me a long time to be diagnosed… I wouldn’t like
other people to go through the wait and the pain that I
went through’ (P6, interview). Women viewed the trial,
and receiving medical treatment post-surgery, as a
means of ‘gaining control’ over their condition so that
they could ‘get their life back’. Women also reported en-
rolling in the trial out of ‘desperation’ and a willingness
to ‘try anything’ to manage the condition.
Overwhelmingly, women found the 3-year length of
their participation acceptable as this long study reflects
the chronic nature of endometriosis and the unpredict-
able nature of symptoms that vary between women and
over different stages of an individual’s life. Further, they
viewed the relatively long time period as a positive both
for themselves as individuals, as the efficacy of their
post-surgery treatment would be monitored over the
course of 3 years, as well as for the overall success of the
trial. Women felt it took time for their bodies to ‘get
used to’ hormonal treatments (or to the absence of hor-
monal treatment) and for negative side effects to sub-
side. Some of those who had undergone previous
laparoscopic surgery for endometriosis felt that this
alone reduced pain for 2 to 3 years. Thus, the trial
length was seen as advantageous to allow both for the
efficacy of post-surgery treatments to be considered in
light of this ‘adjustment period’ and for the decline in
the effectiveness of surgery to reduce pain over time.
Only one woman expressed a concern about the trial
length, stating that some participants may wish to be-
come pregnant during this time and would thus need to
withdraw from the study. Others indicated that they did
not view their participation as irrevocable, as a change
in personal circumstances could precipitate a change in
treatment decisions.
Discussion
The aim of the study was to explore women’s experience
of medical treatments for endometriosis symptoms and
the impact this has on their motivation to enter a clin-
ical trial post conservative surgery. This trial aimed to
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compare existing treatments; no novel therapy was being
offered and so previous and present experience of these
was particularly relevant. Our findings are consistent
with those of McCann et al. who conducted two
metasyntheses of studies which considered reasons for
participation in phase 3 trials over the time periods
1996–2005 and 2005–2010. From these, they identified
four influences on the decision to enter an RCT [22]. In
the first study, (1996–2005) personal circumstances
around the time of recruitment to the study, views of
the trial treatment interventions, views of the trial pro-
cesses and procedures, and weighing up benefit to self
and others all influenced the decision making of pro-
spective participants. From the findings of the second
synthesis (2005–2005), McCann et al. argued that the
first of these influences—where the participant was situ-
ated in terms of ‘health status, treatment juncture and
perceptions of these at the time of recruitment’—medi-
ated ‘the nature and salience of judgements’ about the
other three [22], page 238. In addition, we have demon-
strated how willingness to enter the PRE-EMPT trial
was bound up with previous experience and future
expectations of medication, as well as the control offered
by the option to reject a particular treatment post-surgery.
Overall, women did not report one post-surgery treatment
option (including the no-treatment group) as more un-
acceptable than any others. However, individually, women
had strong feelings about which treatments they found
objectionable based on their past negative experiences, or
those of their friends and family members, with that par-
ticular treatment. These strong treatment preferences
shape participants’ views on randomisation, with half indi-
cating they would have declined the trial if they had not
been allowed the element of choice over which trial op-
tions they would (and would not) be randomised to. Simi-
larly, research on women’s participation in a trial
comparing surgical techniques for stress incontinence
found that non-participants were not averse to clinical tri-
als per se but had strong preferences about specific as-
pects of treatment, in particular for a specific product and
a general anaesthetic [28].
While women’s previous experience of treatment influ-
enced notions of acceptability of different treatments,
poor experience did not necessarily equate with un-
acceptability. Women’s reasoning was complex, with
past experience being weighed against future expectation
of treatment in their decision making. Some women felt
that their changed circumstances (i.e. following surgery)
could lead them to experiencing a more positive result
or changes to the medication itself (e.g. a different
COCP) may result in fewer side effects. That women
were prepared to retry medical treatments that may have
been unsuccessful or had limited success in the past is a
key additional finding. This openness to receive
treatments that have previously been ineffective speaks
to the ‘desperation’ some women reported in their on-
going struggles to find effective interventions and desire
to ‘try anything’ to relieve their condition.
Qualitative thematic analysis highlighted that the com-
plex rationales for which treatment options women
found acceptable need to be understood within the con-
text of their ongoing struggle to find long-term, effective
medical treatments that address their endometriosis
symptoms. Existing quantitative research shows only
weak evidence of the effectiveness of many medical
treatments for managing endometriosis pain [4]. Add-
itionally, a Cochrane review for endometriosis found
only low to moderate evidence for many medical treat-
ments, including suppression of menstrual cycles
through GnRH analogues, LNG-IUS and Danazol, con-
firming the limited effectiveness of commonly prescribed
interventions [6] Although our study only asked women
about their experience of the treatment options in the
trial, the analysis highlights the patients’ perspective in
navigating this myriad of often ineffective medical treat-
ments available. It demonstrates that the complexity of
women’s reasoning for wholly rejecting some treatment
options, while sometimes accepting others they also had
previous negative experiences with, is based on their on-
going attempts with multiple medical treatments, each
with varied efficacy over time.
Past qualitative research has shown that prior to diag-
nosis, women report enduring their endometriosis symp-
toms for years (7–11) and ‘suffer at a physical, emotional
and social level’ when they remain undiagnosed [9].
Within this body of literature, it has also been noted that
women may be taking medications that are often used to
treat endometriosis, and this can mask symptoms of the
condition and contribute to delayed diagnosis [9, 10, 12].
These delays occur both at an individual patient level
and a medical level [9, 14] and commonly feature the
normalisation of women’s pain [9, 14]. Post-diagnosis,
qualitative studies of endometriosis experiences show
that women report limited treatment success and recur-
rent symptom relapses [9, 12–14], creating what has
been termed a ‘medical merry-go-round’ [29]. In relation
to these findings, our analysis demonstrates that the
willingness of participants in this trial to try, and retry,
treatments out of ‘desperation’ likely stems from the
hardships women face in delayed pathways to endomet-
riosis diagnosis and the subsequent merry-go-round of
medical treatments. To what extent women’s experi-
ences of the medical merry-go-round foster these feel-
ings of desperation, and shape their treatment-seeking
practices, warrants further empirical investigation.
Women’s experiences of ongoing cycles of treatment ef-
ficacy and inefficacy are also reflected in findings on par-
ticipants’ views of the PRE-EMPT trial itself. Women
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made sense of the length of their trial participation
(3 years) in terms of their own benefit as well as of the
success of the overall trial. Women’s experience of the
long-term nature of endometriosis and the short- or
medium-term effect of treatments was seen as good jus-
tification for a long follow-up period.
This study sheds light on the rationales underpinning
patients’ decisions to enter clinical trials, which may be
helpful to future studies. The ability to recruit and retain
suitable participants to research, and in particular to ran-
domised trials, remains a major concern [21]. Qualitative
methods used early in the research process have been
shown to improve recruitment, by addressing concerns
that are identified by participants in preparatory work, in
order to increase the relevance and acceptability of partici-
pating in RCTs [30]. This study demonstrates that re-
searchers would benefit from considerations of the
complex ways in which participants’ past histories, current
circumstances and future hopes with treatments offered
in a trial comes to influence acceptability. Women in this
trial were open to retrying treatments with which they
had past negative or ambivalent experiences, especially in
light of changed circumstances (in this case, the potential
for the increased efficacy of treatments post laparoscopic
surgery). Such findings are useful for recruitment strat-
egies and can potentially inform how women are offered
various treatment arm options. They also demonstrate
how the processes by which the research is conducted
may be designed to offer an element of choice and/or con-
trol to participants.
Results from this qualitative study also highlight the im-
portance of increased choice offered to patients through
the option to ‘opt out’ of a particular treatment arm (or
arms). This element of choice offered patients an import-
ant sense of control in the randomisation process and is
important to consider where there are strong preferences
among potential trial recruits. Past qualitative research
has repeatedly shown that the issue of control is particu-
larly important to women living with endometriosis, as it
has been described as a disease that causes individuals to
feel a loss of control over their bodies and their lives [10,
11, 17, 29, 31]. Furthermore, this research highlights that
women view taking action through medical (as well as
complementary) treatments as a means of reclaiming lost
control [11, 17]. Thus, our analysis demonstrates that
women actively engaged in the management of their
endometriosis could potentially find randomisation into a
trial without the ability to choose between treatment
arm(s) as unacceptable loss of control over their condi-
tion. Knowledge of the importance of this element of
choice to patients can also be considered in the design the
clinical trials and help improve overall recruitment. Flex-
ible trial designs have proved beneficial in other trial situa-
tions, allowing multiple questions to be simultaneously
addressed [32, 33]. However, flexibility is often provided
to accommodate clinician preferences or practice, rather
than those of the participants.
Strength and limitations
As far as we are aware, this is the first qualitative study
to have experience of medical treatments for endometri-
osis as its main focus. Using a qualitative research design
has enabled us to gain insight into this experience and
how women make sense of participation in a clinical
trial within this context. Using two research methods
has increased methodological rigour: however, a focus
group of under six participants is below the generally
agreed minimum [24]. The main limitation of the study
is that participants were drawn only from women who
had agreed to be randomised to the PRE-EMPT trial.
Women who declined to participate, the two women
who did not attend the FG and women who are success-
fully managed with medication may have different per-
spectives on living with endometriosis. Research into
why people with long-term conditions decline to take
part in trials is limited but include not wanting disrup-
tion to their lives, for example by extra clinic visits, or
their state of health at the time of being approached
[34], and the unknown of a clinical trial [35].
PRE-EMPT trial participants are to be followed up for
3 years, and during this time, women are likely to be on
conception-preventing drugs. It is therefore probable that
this would be an additional reason women for whom fer-
tility is a key issue would not be represented in the study.
Conclusion
Women in this study demonstrate complex pathways to
decision making regarding which treatments for endo-
metriosis they find acceptable, and this shapes their
willingness to enter a clinical trial for post-surgery treat-
ments to prevent symptom reoccurrence. In addition to
a mix of altruism and self-interest, women entered the
PRE-EMPT trial because of the ability to ‘opt out’ of treat-
ment arm(s) they found unacceptable. This element of
choice offered patients a sense of control in the random-
isation process and has important implications for clinical
trial design and recruitment. By not only including partici-
pants in the early stages of research design but also by
allowing them to articulate their own decision-making
processes in assessing treatment options and trial partici-
pation, researchers in many areas of health research may
optimise recruitment and retention. In terms of endomet-
riosis policy, it needs to be acknowledged that many
women have been on a long journey, and their accumu-
lated knowledge of what works, what does not and at what
personal cost needs to be included at the micro and macro
levels of policy making.
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